drugset
Drugs / 25(OH)D3
last change Nov 2021 re-read 3 minutes ago

25(OH)D3

also known as 25-hydroxyvitamin D3 · Vigantol
Developed for
vitamin D deficiency · congestive heart failure
Investigated by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Semmelweis University · University of California, Los Angeles

Trials 2

today NCT02091219 · Ph 0 NCT01535196 · Ph 3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02091219 Jun 2014 → Dec 2019 vitamin D deficiency University of California, Los Angeles Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01535196 Dec 2012 → May 2017 congestive heart failure, vitamin D deficiency Semmelweis University Terminated No outcome recorded Stop: Enrollment

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as 25-OH-D3 “Type of drug: 180 000 IU 25-OH-D3 vitamin oil (Vigantol) per month in the 0,1,2,3,6, month” NCT01535196 ↗
1

NCT02091219 ↗
Known as 25-hydroxyvitamin D3 “To determine whether correcting vitamin D deficiency with cholecalciferol (vitamin D3, D3) or calcifediol (25-hydroxyvitamin D3, 25(OH)D3) changes gut microbiome composition.” PMID 34343292 ↗ Nov 2021
Known as Vigantol “Type of drug: 180 000 IU 25-OH-D3 vitamin oil (Vigantol) per month in the 0,1,2,3,6, month” NCT01535196 ↗
Route Oral “180 000 IU 25-OH-D3 vitamin oil per os, per month” NCT01535196 ↗